Key points are not available for this paper at this time.
BACKGROUND: The effect of high-flow nasal cannula (HFNC) therapy in patients after planned extubation remains inconclusive. We aimed to perform a rigorous and comprehensive systematic meta-analysis to robustly quantify the benefits of HFNC for patients after planned extubation by investigating postextubation respiratory failure and other outcomes. METHOD: We searched MEDLINE, EMBASE, Web of Science, and the Cochrane Library from inception to August 2018. Two researchers screened studies and collected the data independently. Randomized controlled trials (RCTs) and crossover studies were included. The main outcome was postextubation respiratory failure. RESULTS: , mortality in ICU and hospital, and severe adverse events between HFNC and COT group. CONCLUSIONS: , and be safely administered in patients after planned extubation. Further large-scale, multicenter studies are needed to confirm our results.
Zhu et al. (Fri,) studied this question.